Arcadia Biosciences, Inc. (RKDA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of RKDA were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No RKDA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RKDA short interest
Low short interest. 4.8% of RKDA shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went up 1173%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 115,580 RKDA shares were sold short, 4.8% of the shares outstanding, down 66.3% from the report before. At the average daily volume of 766,639 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 115,580 | 4.80% | -66% | 766,639 | 1.0 |
| Oct 15, 2026 | 342,847 | 14.23% | +286% | 5.31M | 1.0 |
| Sep 30, 2026 | 88,752 | 3.68% | +824% | 4.63M | 1.0 |
| Sep 15, 2026 | 9,605 | 0.40% | -49% | 54,883 | 1.0 |
| Aug 31, 2026 | 18,768 | 0.78% | -79% | 183,620 | 1.0 |
| Aug 14, 2026 | 88,674 | 3.68% | +2437% | 307,856 | 1.0 |
| Jul 31, 2026 | 3,495 | 0.17% | -64% | 15,605 | 1.0 |
| Jul 15, 2026 | 9,653 | 0.47% | -59% | 133,939 | 1.0 |
| Jun 30, 2026 | 23,325 | 1.13% | -91% | 95,314 | 1.0 |
| Jun 15, 2026 | 273,134 | 13.28% | -34% | 11.30M | 1.0 |
| May 29, 2026 | 411,143 | 19.99% | +4427% | 6.75M | 1.0 |
| May 15, 2026 | 9,082 | 0.44% | +43% | 41,016 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Arcadia Biosciences company events
Arcadia Biosciences filed 13 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing, auditor). The latest was on Sep 15, 2026.
- Sep 15, 2026Leadership2026 Omnibus Equity Incentive Plan As further described in Item 5.07 below, the stockholders of Arcadia Biosciences, Inc. approved the Company’s 2026 Omnibus Equity Incentive Plan at the Company’s 2026 Annual Meeting of Stockholders held on September 10, 2026. Filing
- Sep 4, 2026ListingArcadia Biociences, Inc. received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2026, did not meet the minimum… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Aug 10, 2026ListingArcadia Biosciences, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)… Filing
- Jul 2, 2026LeadershipArcadia Biosciences, Inc. filed an amendment to its Annual Report on Form 10-K/A with the Securities and Exchange Commission. Filing
- Jun 15, 2026AgreementArcadia Biosciences, Inc. entered into a securities purchase agreement with an institutional accredited investor for the sale and issuance in a private placement of (i) pre-funded warrants to purchase up to 3,883,496 shares of common stock of the Company, (ii) Series A-1 preferred investment… Filing
- May 14, 2026ResultsReleased financial results. Filing
- Apr 3, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Feb 6, 2026LeadershipEach of Albert D. Bolles, Ph.D., a director and member of the Compensation Committee of the board of directors of Arcadia Biosciences, Inc., and Deborah Carosella, a director and member of the Compensation Committee and Nominating and Governance Committee of the Board, notified the Company that… Filing
- Jan 14, 2026AgreementArcadia Biosciences, Inc. entered into inducement offer letter agreements with certain investors pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock. Filing
- Dec 29, 2025AgreementEnded an important agreement. Filing
- Dec 23, 2025VoteReported shareholder vote results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Arcadia Biosciences financials
Famous investors that hold RKDA
1 of the 50 well-known investors we track reported holding RKDA in their latest 13F filing. The largest position is Ken Griffin's, worth $6.4K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 22,887 | $6.4K | 0.0% | -4% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RKDA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 10.0% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 10.0% |
Questions about Arcadia Biosciences, Inc. (RKDA) stock
Are RKDA insiders buying or selling?
No RKDA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in RKDA?
As of Oct 30, 2026, 115,580 RKDA shares were sold short, 4.8% of the shares outstanding, down 66.3% from the report before. At the average daily volume of 766,639 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold RKDA?
1 of the 50 well-known investors we track reported RKDA in their latest 13F filing, including Ken Griffin. The largest position is worth $6.4K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.